Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 11/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8288453 | 0.93 | GRIA2 (0.54) | GRIA2GRIA4ALDH1A1MEN1KMT2A | |
| SCHEMBL8289843 | 0.92 | GRIA2 (0.53) | GRIA2GRIA4ALDH1A1 | |
| SCHEMBL8289509 | 0.92 | GRIA2 (0.54) | GRIA2GRIA4ALDH1A1POLBMAPT | |
| SCHEMBL8289844 | 0.92 | GRIA2 (0.54) | GRIA2GRIA4ALDH1A1KDM4EMEN1 | |
| SCHEMBL8287386 | 0.92 | GRIA2 (0.48) | GRIA2GRIA4 | |
| SCHEMBL8289413 | 0.92 | GRIA2 (0.52) | GRIA2GRIA4ALDH1A1 | |
| SCHEMBL13611796 | 0.91 | GRIA2 (0.69) | GRIA2GRIA4ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13611815 | 0.87 | GRIA2 (0.53) | GRIA2GRIA4ALDH1A1KDM4EMEN1 | |
| SCHEMBL8289860 | 0.87 | GRIA2 (0.51) | GRIA2GRIA4 | |
| SCHEMBL8288461 | 0.86 | GRIA2 (0.52) | GRIA2GRIA4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA2 17/4885GRIA4 16/4885ALDH1A1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.